1
|
Sicard G, Protzenko D, Giacometti S, Barlési F, Ciccolini J, Fanciullino R. Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet. Br J Cancer 2023; 129:1373-1382. [PMID: 37524968 PMCID: PMC10628115 DOI: 10.1038/s41416-023-02350-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 05/19/2023] [Accepted: 06/27/2023] [Indexed: 08/02/2023] Open
Abstract
BACKGROUND Successful immunotherapy is restricted to some cancers only, and combinatorial strategies with other drugs could help to improve their efficacy. Here, we monitor T cells in NSCLC model after treatment with cytotoxics (CT) and anti-VEGF drugs, to understand when immune checkpoint inhibitors should be best associated next. METHODS In vivo study was performed on BALB/c mice grafted with KLN205 cells. Eight treatments were tested including control, cisplatin and pemetrexed as low (LD CT) and full (MTD CT) dose as single agents, flat dose anti-VEGF and the association anti-VEGF + CT. Full immunomonitoring was performed by flow cytometry on tumor, spleen and blood over 3 weeks. RESULTS Immunomodulatory effect was dependent upon both treatments and time. In tumors, combination groups shown numerical lower Treg cells on Day 21. In spleen, anti-VEGF and LD CT group shown higher CD8/Treg ratio on Day 7; on Day 14, higher T CD4 were observed in both combination groups. Finally, in blood, Tregs were lower and CD8/Treg ratio higher, on Day 14 in both combination groups. On Day 21, CD4 and CD8 T cells were higher in the anti-VEGF + MTD CT group. CONCLUSIONS Anti-VEGF associated to CT triggers notable increase in CD8/Tregs ratio. Regarding the scheduling, a two-week delay after using anti-VEGF and CT could be the best sequence to optimize antitumor efficacy.
Collapse
Affiliation(s)
- G Sicard
- SMARTc & COMPO Team, CRCM Inserm U1068, Aix Marseille University, 13007, Marseille, France
| | - D Protzenko
- SMARTc & COMPO Team, CRCM Inserm U1068, Aix Marseille University, 13007, Marseille, France
| | - S Giacometti
- SMARTc & COMPO Team, CRCM Inserm U1068, Aix Marseille University, 13007, Marseille, France
| | - F Barlési
- School of Medicine, Aix Marseille University, 13007, Marseille, France
- Gustave Roussy Institute, 94800, Villejuif, France
| | - J Ciccolini
- SMARTc & COMPO Team, CRCM Inserm U1068, Aix Marseille University, 13007, Marseille, France.
| | - R Fanciullino
- SMARTc & COMPO Team, CRCM Inserm U1068, Aix Marseille University, 13007, Marseille, France
| |
Collapse
|
2
|
Donnette M, Ciccolini J, Pissier C, Costello R, Duffaud F, Salas S, Farnault L, Tichadou A, Arcani R, Jarrot PA, Ouafik LH, Venton G, Fanciullino R. High incidence of CDA deficiency in patients with hematological malignancies: perspectives and therapeutic implications. Ann Oncol 2021; 32:684-686. [PMID: 33529741 DOI: 10.1016/j.annonc.2021.01.072] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Revised: 12/30/2020] [Accepted: 01/17/2021] [Indexed: 11/29/2022] Open
Affiliation(s)
- M Donnette
- SMARTc, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix-Marseille University, Marseille, France
| | - J Ciccolini
- SMARTc, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix-Marseille University, Marseille, France.
| | - C Pissier
- Laboratoire de Transfert en Oncologie, University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - R Costello
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - F Duffaud
- Medical Oncology Unit, La Timone University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - S Salas
- Medical Oncology Unit, La Timone University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - L Farnault
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - A Tichadou
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - R Arcani
- Internal Medicine Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - P A Jarrot
- Internal Medicine Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - L H Ouafik
- Laboratoire de Transfert en Oncologie, University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - G Venton
- Hematology Unit, La Conception University Hospital of Marseille, Assistance Publique Hôpitaux de Marseille, Marseille, France
| | - R Fanciullino
- SMARTc, Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Aix-Marseille University, Marseille, France
| |
Collapse
|
3
|
Rodallec A, Franco C, Robert S, Sicard G, Giacometti S, Lacarelle B, Bouquet F, Savina A, Lacroix R, Dignat-George F, Ciccolini J, Poncelet P, Fanciullino R. Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles. Sci Rep 2020; 10:4147. [PMID: 32139753 PMCID: PMC7057981 DOI: 10.1038/s41598-020-60856-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2019] [Accepted: 02/06/2020] [Indexed: 12/13/2022] Open
Abstract
Developing targeted nanoparticles is a rising strategy to improve drug delivery in oncology. Antibodies are the most commonly used targeting agents. However, determination of their optimal number at the surface remains a challenging issue, mainly due to the difficulties in measuring precisely surface coating levels when prototyping nanoparticles. We developed an original quantitative assay to measure the exact number of coated antibodies per nanoparticle. Using flow cytometry optimized for submicron particle analysis and beads covered with known amounts of human IgG-kappa mimicking various amounts of antibodies, this new method was tested as part of the prototyping of docetaxel liposomes coated with trastuzumab against Her2+ breast cancer. This quantification method allowed to discriminate various batches of immunoliposomes depending on their trastuzumab density on nanoparticle surface (i.e., 330 (Immunoliposome-1), 480 (Immunoliposome-2) and 690 (Immunoliposome-3), p = 0.004, One-way ANOVA). Here we showed that optimal number of grafted antibodies on nanoparticles should be finely tuned and highest density of targeting agent is not necessarily associated with highest efficacy. Overall, this new method should help to better prototype third generation nanoparticles.
Collapse
Affiliation(s)
- A Rodallec
- SMARTc Unit, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University, Marseille, France
| | - C Franco
- Biocytex, Marseille, France.,Aix-Marseille University, INSERM, INRA, C2VN UMR_S1263, UFR de Pharmacie, Marseille, France
| | - S Robert
- C2VN, AMUTICYT Core facility, INSERM, INRA, Aix-Marseille University, Marseille, France
| | - G Sicard
- SMARTc Unit, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University, Marseille, France
| | - S Giacometti
- SMARTc Unit, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University, Marseille, France
| | - B Lacarelle
- SMARTc Unit, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University, Marseille, France
| | - F Bouquet
- Institut Roche, Boulogne Billancourt, France
| | - A Savina
- Institut Roche, Boulogne Billancourt, France
| | - R Lacroix
- Aix-Marseille University, INSERM, INRA, C2VN UMR_S1263, UFR de Pharmacie, Marseille, France.,Department of Hematology and Vascular Biology, CHU La Conception, APHM, Marseille, France
| | - F Dignat-George
- C2VN, AMUTICYT Core facility, INSERM, INRA, Aix-Marseille University, Marseille, France.,Aix-Marseille University, INSERM, INRA, C2VN UMR_S1263, UFR de Pharmacie, Marseille, France.,Department of Hematology and Vascular Biology, CHU La Conception, APHM, Marseille, France
| | - J Ciccolini
- SMARTc Unit, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University, Marseille, France
| | | | - R Fanciullino
- SMARTc Unit, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University, Marseille, France.
| |
Collapse
|
4
|
Farnault L, Venton G, Pourroy B, Jourde-Chiche N, Ivanov V, Arcani R, Roche P, Mercier C, Colle J, Fanciullino R, Costello RT. Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen. Bone Marrow Transplant 2019; 54:1173-1175. [PMID: 30718799 DOI: 10.1038/s41409-019-0467-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 12/31/2018] [Accepted: 01/22/2019] [Indexed: 11/09/2022]
Affiliation(s)
- L Farnault
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France.
| | - G Venton
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France
| | - B Pourroy
- Pharmacy, ONCOPHARMA Unit, Timone Hospital, University Hospital of Marseille, Marseille, France
| | - N Jourde-Chiche
- Department of Nephrology, La Conception, University Hospital of Marseille, Marseille, France.,UMR_S 1076, Vascular Research Center of Marseille, Marseille, France
| | - V Ivanov
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France
| | - R Arcani
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France
| | - P Roche
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France
| | - C Mercier
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France
| | - J Colle
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France
| | - R Fanciullino
- Pharmacy Unit, La Conception, University Hospital of Marseille, APHM, Marseille, France.,SMARTc Unit, Pharmacokinetics Laboratory, UMR_911 CRO2 AMU, Marseille, France
| | - R T Costello
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, Marseille, France.,Aix Marseille Université, INSERM UMR_S 1090, Technological Advances for Genomics and Clinics, Marseille, France
| |
Collapse
|
5
|
Venton G, Suchon P, Colle J, Baier C, Sanderson F, Poullin P, Ivanov V, Mercier C, Farnault L, Roche P, Arcani R, Fanciullino R, Brunet C, Philip PJM, Costello R. Hematopoietic reconstitution after autologous hematopoietic stem cell transplantation: do CD45 (+) CD34 (+) CD38 (-) progenitors really matter in real life? Transfus Apher Sci 2018; 57:406-408. [PMID: 29709543 DOI: 10.1016/j.transci.2018.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 03/30/2018] [Accepted: 04/04/2018] [Indexed: 10/17/2022]
Affiliation(s)
- G Venton
- INSERM, UMR1090 TAGC,Marseille, F_13288,France; Aix-Marseille University, UMR1090 TAGC,Marseille, F_13288,France; Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - P Suchon
- Hematology laboratory, La Timone, University Hospital of Marseille, France; UMR 1062 NORT, INSERM, Marseille France
| | - J Colle
- INSERM, UMR1090 TAGC,Marseille, F_13288,France; Aix-Marseille University, UMR1090 TAGC,Marseille, F_13288,France; Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - C Baier
- INSERM, UMR1090 TAGC,Marseille, F_13288,France
| | - F Sanderson
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France; Apheresis and auto transfusion department, la Conception, University Hospital of Marseille, France
| | - P Poullin
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France; Apheresis and auto transfusion department, la Conception, University Hospital of Marseille, France
| | - V Ivanov
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - C Mercier
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France; UMR-911 INSERM, Toxicokinetics andpharmacokinetics laboratory, pharmacological faculty, Marseille, France
| | - L Farnault
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - P Roche
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - R Arcani
- Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France
| | - R Fanciullino
- SMARTc Unit, Pharmacokinetics Laboratory, UMR_911 CRO2 AMU Marseille, France; Pharmacy Unit, La Conception University Hospital of Marseille, APHM, Marseille, France
| | - C Brunet
- Hematology laboratory, La Conception, University Hospital of Marseille, France
| | - P J M Philip
- Cell therapy unit - The French Blood Establishment (EFS - Provence - Alpes Côte d'Azur - Corse)", Saint Laurent du Var, France
| | - R Costello
- INSERM, UMR1090 TAGC,Marseille, F_13288,France; Aix-Marseille University, UMR1090 TAGC,Marseille, F_13288,France; Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, France.
| |
Collapse
|
6
|
Venton G, Adam H, Colle J, Labiad Y, Mercier C, Ivanov V, Suchon P, Fanciullino R, Farnault L, Costello R. Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia. Med Mal Infect 2016; 46:226-9. [PMID: 27126350 DOI: 10.1016/j.medmal.2016.03.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Revised: 01/29/2016] [Accepted: 03/18/2016] [Indexed: 10/21/2022]
Abstract
OBJECTIVE To study the efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing induction chemotherapy for acute myeloid leukemia. PATIENTS AND METHODS A prospective observational single-center study of 41 patients from the hematology department between May 2012 and April 2015. Micafungin was administered once daily from the first day of induction chemotherapy to the end of the neutropenic phase. RESULTS Neither Candida nor Aspergillus infection was documented in our 41 patients from the first day of micafungin infusion to the end of the neutropenic phase. Patients were followed for three months after discontinuation of micafungin and none of them contracted an invasive fungal infection. Only one patient presented with grade III-IV hepatic and ionic toxicities. CONCLUSION Micafungin is associated with a good safety profile and is an interesting option for preventing invasive fungal infections in the high-risk population of patients presenting with hematological disorders.
Collapse
Affiliation(s)
- G Venton
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - H Adam
- Unité pharmacie hospitalière hôpital de la Conception, Marseille, France
| | - J Colle
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - Y Labiad
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France
| | - C Mercier
- Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France; UMR-911 Inserm laboratoire de toxicocinétique et pharmacocinétique, faculté de pharmacie, Marseille, France
| | - V Ivanov
- Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - P Suchon
- Laboratoire d'hématologie, AP-HM, hôpital de la Timone, Marseille, France; UMR 1062 NORT, Inserm, Marseille, France
| | - R Fanciullino
- UMR-911 Inserm laboratoire de toxicocinétique et pharmacocinétique, faculté de pharmacie, Marseille, France; Unité pharmacie hospitalière hôpital de la Conception, Marseille, France
| | - L Farnault
- Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France
| | - R Costello
- Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France.
| |
Collapse
|
7
|
Sicard G, Protesti E, Fanciullino R, Darque A, Buffat C, Gensollen S. P-540 – Mise en place d'un protocole de reconstitution de l'aciclovir en Néonatologie. Arch Pediatr 2015. [DOI: 10.1016/s0929-693x(15)30715-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
Etienne-Grimaldi MC, Couvreur P, Benoit JP, Fanciullino R, Sergent JA, van Miert E, Pourroy B, Meshaka P, Brescianini A, Corvaia N, Haeuw JF, Goetsch L, Beck A. Médicaments de haute technologie en oncologie. ONCOLOGIE 2014. [DOI: 10.1007/s10269-014-2417-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
9
|
Tagourdeau S, Chiche L, Lanfranchi MA, Brah S, Eldin C, Jean R, Thomas G, Bornet C, Fanciullino R, Harle JR, Pastor MJ, Durand JM. Hyopglycémies secondaires à la prise de tramadol : deux nouveaux cas. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.03.212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
10
|
Fanciullino R. Nanotechnologies et onco-pharmacologie ? Arch Pediatr 2011. [DOI: 10.1016/s0929-693x(11)70958-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Brah S, Fanciullino R, Loustalot MC, Bornet C, Mancini J, Thomas G, Harle JR, Durand JM, Kaplanski G, Chiche L. Utilisation dans la « vraie vie » du rituximab pour le traitement des thrombopénies auto-immunes : étude monocentrique sur 40 cas. Rev Med Interne 2010. [DOI: 10.1016/j.revmed.2010.10.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Fanciullino R, Ciccolini J. Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr Med Chem 2010; 16:4361-71. [PMID: 19835568 DOI: 10.2174/092986709789712916] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2009] [Accepted: 09/24/2009] [Indexed: 11/22/2022]
Abstract
Anticancer drugs are essential agents in the global strategy developed to fight cancer. Still, narrow therapeutic indices, erratic pharmacokinetics profiles and lack of selectivity towards malignant tissues often hamper their efficacy at the bedside, when they not cause severe toxicities. In this respect, developing innovative drug delivery strategies that would selectively target malignant tissues is still an ongoing story, both in experimental and in clinical oncology. Delivery systems such as liposomes are usually required when an existing formulation is not satisfactory, because encapsulation is expected to provide higher therapeutic efficacy and safety. Such significant improvement in therapeutic efficacy and/or therapeutic indices has already been achieved in patients with some liposome-encapsulated drugs such as anthracyclines. It is now possible to develop a wide range of vectors varying in size, composition, and surface morphology suitable for a variety of therapeutic applications, including for targeting tumor tissues. Reformulation of anticancer drugs in liposomes remains a challenging opportunity to stretch the therapeutic indices of many cytotoxic drugs, through the optimization of their distribution in the body. Despite these promising and exciting perspectives in oncology, to date only few drugs (e.g., anthracyclines) have actually made their way as liposomes from the bench to the bedside. However, as target therapies have brought a new hope in the cancer war in the 2000's, developing now targeted delivery systems is more and more seen as the next step to further improve clinical outcome in cancer patients. This review covers the achievements, limits, and new expectancies of anticancer drugs as candidates for liposomal encapsulation.
Collapse
Affiliation(s)
- R Fanciullino
- UFR Pharmacie, 27 Bd Jean Moulin, 13385 Marseille Cedex 05, France
| | | |
Collapse
|
13
|
Fanciullino R, Giacometti S, Mercier C, Aubert C, Blanquicett C, Piccerelle P, Ciccolini J. In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation. Br J Cancer 2007; 97:919-26. [PMID: 17848948 PMCID: PMC2360412 DOI: 10.1038/sj.bjc.6603970] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Drug resistance is a major cause of treatment failure in cancer chemotherapy, including that with the extensively prescribed antimetabolite, 5-fluorouracil (5-FU). In this study, we tried to reverse 5-FU resistance by using a double-punch strategy: combining 5-FU with a biochemical modulator to improve its tumoural activation and encapsulating both these agents in one same stealth liposome. Experiments carried out in the highly resistant, canonical SW620 human colorectal model showed a up to 80% sensitisation to 5-FU when these cells were treated with our liposomal formulation. Results with this formulation demonstrated 30% higher tumoural drug uptake, better activation with increased active metabolites including critical-5-fluoro-2-deoxyuridine-5-monophosphate, superior inhibition (98%) of tumour thymidylate synthase, and subsequently, higher induction of both early and late apoptosis. Drug monitoring showed that higher and sustained exposure was achieved in rats treated with liposomal formulation. When examined in a xenograft animal model, our dual-agent liposomal formulation caused a 74% reduction in tumour size with a mean doubling in survival time, whereas standard 5-FU failed to exhibit significant antiproliferative activity as well as to increase the lifespan of tumour-bearing mice. Taken collectively, our data suggest that resistance to 5-FU can be overcome through a better control of its intratumoural activation and the use of an encapsulated formulation.
Collapse
Affiliation(s)
- R Fanciullino
- EA3286-Laboratoire de Pharmacocinétique, Université de la Méditerranée, Marseille, France
| | - S Giacometti
- EA3286-Laboratoire de Pharmacocinétique, Université de la Méditerranée, Marseille, France
| | - C Mercier
- EA3286-Laboratoire de Pharmacocinétique, Université de la Méditerranée, Marseille, France
| | - C Aubert
- EA3286-Laboratoire de Pharmacocinétique, Université de la Méditerranée, Marseille, France
| | - C Blanquicett
- Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA
| | - P Piccerelle
- Laboratoire de Pharmacie Galénique, Faculté de Pharmacie, 27 Bd Jean Moulin, Marseille 05 13385, France
| | - J Ciccolini
- EA3286-Laboratoire de Pharmacocinétique, Université de la Méditerranée, Marseille, France
- EA3286, Laboratoire de Pharmacocinétique, Faculté de Pharmacie, 27 Bd Jean Moulin 13385, Marseille 05, France. E-mail:
| |
Collapse
|